PROM1 and neoplasm: CD133 is also useful in predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer [27], suggesting that CD133 expression may be of help in more accurately predicting the aggressive properties and in determining the optimal therapeutic strategy for this neoplasia.